Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1. Chan, A.
2. Delaloge, S.
3. Holmes, F.A.
4. Moy, B.
5. Iwata, H.
6. Harvey, V.J.
7. Robert, N.J.
8. Silovski, T.
9. Gokmen, E.
10. von Minckwitz, G.
11. Ejlertsen, B.
12. Chia, S.K.L.
13. Mansi, J.
14. Barrios, C.H.
15. Gnant, M.
16. Buyse, M.
17. Gore, I.
18. Smith, J.
19. Harker, G.
20. Masuda, N.
21. Petrakova, K.
22. Zotano, A.G.
23. Iannotti, N.
24. Rodriguez, G.
25. Tassone, P.
26. Wong, A.
27. Bryce, R.
28. Ye, Y.
29. Yao, B.
30. Martin, M.
31. Mostrar todos los/as autores/as +